98%
921
2 minutes
20
We report a case of pathological complete response to neoadjuvant chemotherapy for abscess-forming rectal cancer. A woman in her 60s visited her primary care physician because she noticed an increase in the quantity of vaginal discharge. An irregular mass of goose-egg size found on the right vaginal wall was diagnosed as adenocarcinoma on biopsy, and she was referred to our hospital. After further examination, the mass was diagnosed as RbP, cT4b(vaginal), cN1a, cM0, cStage Ⅲc rectal cancer with abscess formation. After 6 courses of CAPOX as neoadjuvant chemotherapy, rectal resection(combined resection of the posterior vaginal wall) was performed. Pathological diagnosis showed no tumor cells and lymph node metastasis. Four courses of CAPOX were administered as postoperative adjuvant chemotherapy. The patient is still alive 4 years after surgery, without recurrence. When neoadjuvant chemotherapy is successful, radical resection is possible, even in cases with abscess formation, and long-term survival can be expected.
Download full-text PDF |
Source |
---|
Ophthalmic Plast Reconstr Surg
September 2025
Orbital Oncology and Ophthalmic Plastic Surgery, Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center.
Solitary fibrous tumor, formerly also referred to as hemangiopericytoma, is a fibroblastic mesenchymal neoplasm of the orbit that rarely metastasizes but has a propensity for local recurrence. We describe 5 cases of orbital solitary fibrous tumors that were treated with radiation. In 3 patients, radiation therapy was given in the neoadjuvant setting prior to surgery.
View Article and Find Full Text PDFOphthalmic Plast Reconstr Surg
September 2025
Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, U.S.A.
This study aimed to report clinical outcomes of topical chemotherapy for ocular adnexal sebaceous carcinoma (OaSC) with intraepithelial spread. A retrospective chart review of patients with OaSC treated at the Bascom Palmer Eye Institute between 2000 and 2023 was conducted. Patient inclusion criteria included: (1) biopsy-proven diagnosis of OaSC, (2) intraepithelial pagetoid involvement confirmed by conjunctival map biopsy, (3) implementation of topical chemotherapy for tumor control, and (4) repeat conjunctival map biopsy following cessation of topical chemotherapy.
View Article and Find Full Text PDFJ Pediatr Hematol Oncol
September 2025
Department of Pediatric, The University of Jordan.
Background: Rhabdomyosarcoma (RMS) typically responds well to a combination of treatments with favorable prognosis in children 1 to 9 years old. However, infants may fare worse due to receiving less aggressive local therapy for concerns about long-term effects of surgery/radiation. This study investigates the clinical characteristics, treatment approach, and survival outcomes of RMS in children under 2.
View Article and Find Full Text PDFInt J Surg Pathol
September 2025
Department of Pathology, Tata Memorial Hospital & Advanced Centre for Treatment and Research, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
Undifferentiated carcinomas with osteoclast-like giant cells of the pancreaticobiliary tract (UCOGCs) are rare but distinctive tumors with limited literature. To study the clinicopathologic characteristics of UCOGCs including morphology, immunohistochemistry (IHC), management, and survival outcomes. Assessment of 12 patients of UCOGC found over 10 years from a tertiary care oncology center database.
View Article and Find Full Text PDFOncologist
September 2025
Department of Breast Cancer Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, China.
Background: THP (trastuzumab + paclitaxel + pertuzumab) and THPy (trastuzumab + paclitaxel + pyrotinib) are widely used as first-line regimens for human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) in China. However, direct comparative data on their efficacy and safety remain scarce. This study evaluates and compares the clinical outcomes of THPy and THP in the first-line treatment of HER2-positive MBC to guide clinical decision-making.
View Article and Find Full Text PDF